- Home
- IPAR vs GH Comparison
IPAR vs GH Comparison
Compare IPAR & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPAR
- GH
- Stock Information
- Founded
- IPAR 1982
- GH 2011
- Country
- IPAR United States
- GH United States
- Employees
- IPAR N/A
- GH N/A
- Industry
- IPAR Package Goods/Cosmetics
- GH Medical Specialities
- Sector
- IPAR Consumer Discretionary
- GH Health Care
- Exchange
- IPAR Nasdaq
- GH Nasdaq
- Market Cap
- IPAR 4.2B
- GH 4.9B
- IPO Year
- IPAR 1988
- GH 2018
- Fundamental
- Price
- IPAR $132.25
- GH $49.14
- Analyst Decision
- IPAR Strong Buy
- GH Strong Buy
- Analyst Count
- IPAR 5
- GH 20
- Target Price
- IPAR $157.60
- GH $54.35
- AVG Volume (30 Days)
- IPAR 195.6K
- GH 2.2M
- Earning Date
- IPAR 08-05-2025
- GH 08-06-2025
- Dividend Yield
- IPAR 2.42%
- GH N/A
- EPS Growth
- IPAR 19.12
- GH N/A
- EPS
- IPAR 5.17
- GH N/A
- Revenue
- IPAR $1,467,181,000.00
- GH $773,996,000.00
- Revenue This Year
- IPAR $5.90
- GH $23.14
- Revenue Next Year
- IPAR $3.25
- GH $21.42
- P/E Ratio
- IPAR $25.63
- GH N/A
- Revenue Growth
- IPAR 10.32
- GH 28.20
- 52 Week Low
- IPAR $97.65
- GH $20.14
- 52 Week High
- IPAR $148.15
- GH $52.92
- Technical
- Relative Strength Index (RSI)
- IPAR 49.74
- GH 62.17
- Support Level
- IPAR $135.84
- GH $48.00
- Resistance Level
- IPAR $142.61
- GH $51.71
- Average True Range (ATR)
- IPAR 3.36
- GH 2.67
- MACD
- IPAR -1.37
- GH 0.39
- Stochastic Oscillator
- IPAR 16.11
- GH 78.60
About IPAR Inter Parfums Inc.
Interparfums Inc operates in the fragrance business and produces and distributes a wide array of prestige fragrance and fragrance-related products. It sells its product under the brand which includes Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade, Lacoste, Lanvin, Moncler, Montblanc, Rochas and Van Cleef & Arpels. The company operates in two operating segments namely European based operations, SA, and United States based operations.. The group sells its products to department stores, perfumeries, specialty stores, and domestic and international wholesalers and distributors.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.